banter and General Discussion, page-8500

  1. 8,127 Posts.
    lightbulb Created with Sketch. 1407
    "They need to generate more data from real patients"

    Exactly.

    This is why the FDA recommended another RCT twice. This is why the FDA didn't simply say "validate your potency and it's fine".

    This is why MSB has announced they will link the potency assay to the next trial - they need to validate it with new data.

    All of this post hoc biomarker analysis is simply looking at correlation - its hypothesis generating, again. There are statistical reasons for this.

    It needs to be tested, MSB knows this and is finally doing a trial (though not an RCT).

    The FDA knows this, and, IMO, will wait for that data before approving for kids.

    Good analysis JB
    Last edited by DocMcstuffins: 13/01/24
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.62
Change
-0.060(3.58%)
Mkt cap ! $2.063B
Open High Low Value Volume
$1.67 $1.68 $1.62 $8.379M 5.142M

Buyers (Bids)

No. Vol. Price($)
3 76559 $1.62
 

Sellers (Offers)

Price($) Vol. No.
$1.62 676 1
View Market Depth
Last trade - 16.10pm 03/07/2025 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.